정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
51 | Recruiting | Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection | Interstitial Lung Disease | Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF) Device: Centricyte 1000 Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution Drug: Liberase Enzyme (Roche) Drug: Sterile Normal Saline for Intravenous Use |
Early Phase 1 | Black Tie Medical, Inc., Robert W. Alexander, MD | INDUSTRY | 10 | All | 18 Years ~ 90 Years | Robert W. Alexander, MD, FICS, LLC, Stevensville, Montana, United States |
50 | Not yet recruiting | Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection | Covid 19 | Drug: Desferal 500 MG Injection | Phase 4 | Hesham Al-Inany | OTHER | 200 | All | ||
49 | Withdrawn | Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection | Palliative Situation | Drug: Treatment with Dexmedetomidine | Phase 4 | University Hospital, Limoges | OTHER | 0 | All | 18 Years | University Hospital, Limoges, France |
48 | Not yet recruiting | Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS | Acute Respiratory Distress Syndrome | Biological: Human umbilical cord mesenchymal stem cells + best supportive care Other: Placebo control + best supportive care |
Phase 2 | Baylx Inc. | INDUSTRY | 39 | All | 18 Years ~ 80 Years | |
47 | Withdrawn | Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19) | Pulmonary Disease | Drug: Hydroxychloroquine Sulfate Drug: Hydroxychloroquine Sulfate + Azythromycin |
Phase 3 | Apsen Farmaceutica S.A., Federal University of Sao Paulo | INDUSTRY | 0 | All | 18 Years | Apsen Farmaceutica S.A., Sao Paulo, Brazil |
46 | Not yet recruiting | Use of Hypochlorous Acid as Prophylaxis in Health Personnel at High Risk of Infection by SARS-CoV 2 (COVID19) | Infection Viral | Drug: Stabilized hypochlorous acid Drug: Placebo |
Phase 3 | Hospital Universitario San Ignacio, Pontificia Universidad Javeriana | OTHER | 556 | All | 18 Years ~ 80 Years | |
45 | Recruiting | Use of Inhaled High-molecular Weight Hyaluronan in Patients With Severe COVID19: Feasibility and Outcomes | Covid19 | Drug: HMW-HA | Phase 2 | Campus Bio-Medico University, National Institute of Environmental Health Sciences (NIEHS) | OTHER | 200 | All | 18 Years | Universita Campus Biomedico di Roma, Roma, Italy |